Bregt S Kappelhoff - Concepedia

Author

Bregt S Kappelhoff

Also Known As

2NN Study Group, B S Kappelhoff, B. Kappelhoff, B. S. Kappelhoff, B.S. Kappelhoff, Bregt Kappelhoff, Bregt S Kappelhoff, Bregt S. Kappelhoff, for the 2NN study group

Publications

901

Citations

H-Index

Concepts

All Affiliations

Slotervaartziekenhuis Utrecht University Amsterdam UMC Location University of Amsterdam Boehringer Ingelheim (Netherlands)Boehringer Ingelheim (United States)

About

Bregt S Kappelhoff is an author at Slotervaartziekenhuis specializing in medicine, pharmacotherapy, and hiv.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	192
2	Pharmacology	2	2	129
3	Epidemiology	1	1	53
4	Orthopaedics	1	1	10
5	Antimicrobial Pharmacokinetics	1	1	71

Bregt S Kappelhoff

Publications

385

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy Frank van Leth, Bregt S Kappelhoff, David W. Johnson, AIDS Research and Human Retroviruses	2006	81
Population pharmacokinetics of lopinavir in combination with ritonavir in HIV‐1‐infected patients Kristel M. L. Crommentuyn, Bregt S Kappelhoff, Jan W. Mulder, British Journal of Clinical Pharmacology Ritonavir Plasma ConcentrationsPharmacotherapyPopulation PharmacokineticsAntiviral DrugPhysiologically-based Pharmacokinetic Modeling	2005	71
Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography Bregt S Kappelhoff, Hilde Rosing, Alwin D. R. Huitema, Journal of Chromatography B Diagnostic VirologyMedicineDrug DiscoveryAntiviral Drug DevelopmentAntiviral Therapy	2003	58
Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals Bregt S Kappelhoff, Alwin D. R. Huitema, Zeynep Yalva, Clinical Pharmacokinetics Hiv-1-infected IndividualsHuman RetrovirusUnselected CohortAntiviral Drug DevelopmentAntiviral Therapy	2005	53
Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV‐1‐infected patients Bregt S Kappelhoff, Alwin D. R. Huitema, Kristel M. L. Crommentuyn, British Journal of Clinical Pharmacology	2004	39
Pharmacokinetics of Nevirapine: Once-Daily Versus Twice-Daily Dosing in the 2NN Study Bregt S Kappelhoff, Alwin D. R. Huitema, Frank van Leth, HIV Clinical Trials	2005	27
Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV‐1‐infected patients Bregt S Kappelhoff, Alwin D. R. Huitema, Sanjay U.C. Sankatsing, British Journal of Clinical Pharmacology	2005	22
Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands Jelena Stevanović, Lisa A. de Jong, Bregt S Kappelhoff, PLoS ONE	2016	14
Practical Guidelines to Interpret Plasma Concentrations of Antiretroviral Drugs Bregt S Kappelhoff, Alwin D. R. Huitema, Jos H. Beijnen Clinical Pharmacokinetics	2005	10
Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands Maarten J. Postma, Bregt S Kappelhoff, Marinus van Hulst, Journal of Medical Economics Dabigatran EtexilateSurgeryPharmacotherapyOrthopaedic SurgeryThrombosis	2012	10

Page 1